Oriola and Shire Sweden AB, have signed a long-term cooperation agreement. Oriola offers Shire pharmaceutical storage and distribution services and a broad range of tailored services in Sweden.
As of March 1st, 2016, Oriola took over the warehousing and distribution of Shire products in Sweden. Shire enables people with life-altering conditions to lead better lives. It focuses on developing and delivering innovative medicines for patients with rare diseases and other extraordinary conditions. This might be a therapy to treat an extremely rare and life-threatening disease such as Hunter syndrome or Fabry disease, or a medicine for an extraordinary condition such as ADHD or ulcerative colitis.
During the second half of 2016, Shire expects to merge with Baxalta, creating the global leader for therapies in rare diseases.
"This agreement further strengthens the relationship between our two companies and provides a platform for Shire to consolidate its storage and distribution requirements with one strategic partner in Sweden" said Colum Meehan, Associate Director, Supply Chain Distribution, Shire. "Oriola have offered Shire a long term solution and we look forward to benefiting from their knowledge and extensive experience distributing pharmaceutical products across the Nordic region".
"We are very proud to hear from Shire how positive they are about Oriola's logistics service offer and our way to manage customer relations. We are now looking forward to a long-term partnership!" says Fredrik Pamp, Business Unit Director, Services Sweden.
Business Unit Director
tel. +46 (0)706-77 87 23
Associate Director, Supply Chain Distribution
tel. +353 1 429 7718
Oriola - The Channel for Health
Oriola provides services for healthcare actors who want to succeed in the Nordic and Baltic countries. Oriola focuses on long-term customer relationships and wide service offering covering pharmaceutical distribution, branded products and other tailored services. Oriola is part of Finnish Oriola-KD Group. Oriola-KD provides pharmaceutical companies an effective access to markets and improves consumers' wellbeing by ensuring that pharmaceuticals, health products and services are delivered in a safe and customer-friendly manner. Oriola-KD's net sales for continuing operations in 2015 were approximately EUR 1.6 billion. Company has approximately 2,350 employees. Oriola-KD is listed on NASDAQ OMX Helsinki Ltd. For more information, visit www.oriola-kd.com.